My laboratory is investigating kinase modulation of cellular signaling pathways driven by oncogenic mutant proteins. To screen combinations of targeted agents in the setting of specific genetic alterations, novel mouse models of colorectal cancer including tumors driven by a constitutively active PI3K [Cancer Research, 2012; PLoSOne, 2013; Oncogene, 2013]. In addition to my laboratory research, I have also been active in early phase clinical trials. I have developed the concepts and chaired NCI/CTEP sponsored phase I clinical trials including AZD6244 in combination with cetuximab for KRAS mutant colorectal cancer [ASCO Annual Meeting, 2012] and ABT-888 in combination with capecitabine and oxaliplatin for BRCA mutant tumors and gastrointestinal cancers.
Dustin Deming, MD
Clinical Sciences Center
600 Highland Ave
Madison, WI 53792
MD, University of Wisconsin-Madison
I am a gastrointestinal oncologist at the University of Wisconsin Carbone Cancer Center (UWCCC) and the William S Middleton Veterans Hospital. I have a subspecialty focus in the treatment of colon, rectal and anal cancers. My research aims to fundamentally change the way in which we treat gastrointestinal cancers to a more personalized approach.
Deming D, Geiger P, Chen H, Kunnimalayiaan M, and Holen K. ZM336372 induces apoptosis associated with phosphorylation of GSK-3β in pancreatic adenocarcinoma cell lines. Journal of Surgical Research. 2010;161:28-32. PMID: 20031160.
Deming D and Silverman E. Pasteurella Multocida Tracheobronchitis in a Patient with CLL on Rituximab. American Journal of Hematology. 2010;85:144-5. PMID: 20033893.
Leystra A*, Deming D*, Zahm C, Farhoud M, Paul Olson T, Hadac J, Nettekoven L, Albrecht D, Clipson L, Sullivan R, Washington M, Torrealba J, Weichert J, and Halberg R. Mice Expressing Activated PI3K Rapidly Develop Advanced Colon Cancer. Cancer Res. 2012;72:2931-6. PMID: 22525701. * Co-First Authors.
LoConte NK, Holen KD, Schelman WR, Mulkerin DL, Deming DA, Hernan HR, Traynor AM, Goggins T, Groteluschen D, Oettel K, Robinson E, Lubner SJ. A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Invest New Drugs. 2013;31:943-8. PMID: 23263993.
Deming DA, Leystra AA, Farhoud M, Nettekoven L, Clipson L, Albrecht D, Washington MK, Sullivan R, Weichert JP, and Halberg RB. mTOR Inhibition Elicits a Dramatic Response in PI3K-Dependent Colon Cancers. PlosOne. 2013;8:e60709. PMID: 23593290.
Thliveris AT, Schwefel B, Clipson L, Plesh L, Zahm CD, Leystra AA, Washington MK, Sullivan R, Deming DA, Newton MA, and Halberg RB. Transformation of Epithelial Cells through Recruitment Leads to Polyclonal Intestinal Tumors. Proc Natl Acad Sci U S A. 2013;110:11523-8. PMID: 23798428.
Deming DA, Ninan J, Bailey HH, Kolesar JM, Eickhoff J, Reid JM, Ames MM, McGovern RM, Alberti D, Marnocha R, Espinoza-Delgado I, Wright J, Wilding G, and Schelman WR. A phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Invest New Drugs. 2013 Oct 10. [Epub ahead of print] PMID: 24114123.
Deming DA, Leystra AA, Nettekoven L, Seivers C, Miller D, Middlebrooks M, Clipson L, Albrecht D, Bacher J, Washington MK, Weichert J, and Halberg RB. PIK3CA and APC Mutations are Synergistic in the Development of Intestinal Cancers. Oncogene. 2013. [Epub Ahead of Print]. PMID: 23708654.
Paul Olson TJ, Hadac JN, Sievers C, Leystra AA, Deming DA, Zahm CD, Albrecht DM, Nomura A, Nettekoven LA, Plesh LK, Clipson L, Sullivan R, Newton MA, Schelman WR, Halberg RB. Dynamic tumor growth patterns in a novel murine model of colorectal cancer. Cancer Prev Res. 2013 [Epub ahead of print]. PMID: 24196829.
LoConte NK, Deming DA. Mailed invitations for colorectal screening are effective in increasing screening participation in uninsured adults with faecal immunochemical testing: the preferred screening modality. Evid Based Med. 2014 [Epub ahead of print]. PMID: 24727711.